Individually Dose-adjusted FEC Compared to Standard FEC as Adjuvant Chemotherapy for Node Positive or High-risk Node Negative Breast Cancer

Condition:   Breast Cancer Intervention:   Drug: 5-FU, epirubicin and cyclophosphamide Sponsors:   Henrik Lindman;   Scandinavian Breast Cancer Group;   Danish Breast Cancer Group;   Swedish Cancer Society;   Swedish Breast Cancer Association;   Uppsala University Oncology Department Trust;   Pharmacia Pharmaceutical Company;   Swedish Breast Cancer Group Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials